Clinical trials: Tuberculosis Active
Tuberculosis Diagnosis
Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
This study evaluates two portable molecular tests for tuberculosis (TB), Pluslife MTBC and Ustar PortNAT, during community-based active case-finding activities in Pakistan.
- Trial name
- TB (NCT06984887)
- Testing
- Paired tongue-swab and sputum-based molecular testing for tuberculosis
- Where
- 2 sites in Pakistan
- Volunteers
- 6,100 people, healthy volunteers welcome
- Sponsor
- Mercy Corps Pakistan
Tuberculosis
Diagnosis of Active Tuberculosis by ELISPOT
Recent studies revealed that the ex vivo enzyme-linked immunospot (ELISPOT) assay for gamma interferon is a specific method for contact tracing of Mycobacterium tuberculosis infection.
- Trial name
- NCT00174083
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Tuberculosis
The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis
The investigators will evaluate the usefulness of QuantiFERON-TB Gold in-tube (QFT) in the diagnosis of active tuberculosis in young adults group, highly clinically suspected tuberculosis.
- Trial name
- NCT00982969
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Armed Forces Capital Hospital, Republic of Korea
Tuberculosis, Pulmonary
Replacement of Vitamin D in Patients With Active Tuberculosis
Tuberculosis is a global public health problem. One third of the world's population is infected with tuberculosis (TB) with almost 2 million deaths per year globally.
- Trial name
- SUCCINCT (NCT01130311)
- Testing
- Cholecalciferol, Saline injection
- Where
- 4 sites in Pakistan
- Volunteers
- 259 people
- Sponsor
- Aga Khan University
Pulmonary Tuberculosis, Tuberculosis (TB)
Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research
The goal of this observational study is to establish and validate a comprehensive AI-driven clinical decision support system (AI-CDSS) in whole-chain management for pulmonary tuberculosis (TB) patients.
- Conditions
- Pulmonary Tuberculosis, Tuberculosis (TB), Tuberculosis Active
- Trial name
- TB-ATLAS (NCT07611695)
- Where
- 2 sites in China
- Volunteers
- 31,600 people
- Sponsor
- Huashan Hospital
Mycobacterium Tuberculosis Infection
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation)…
- Trial name
- VPM1002 (NCT04351685)
- Testing
- VPM1002, BCG SII
- Where
- 12 sites in Gabon, Kenya and 3 more
- Volunteers
- 6,940 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma
Tuberculosis
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome.
- Trial name
- NCT07595042
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 29 sites in Argentina, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV/AIDS
TB Reduction Through ART and TB Screening Project
Tuberculosis (TB) has overtaken HIV as the leading infectious cause of death worldwide and requires a major policy shift for it to be controlled in line with the WHO Stop-TB goal to "end TB".
- Trial name
- TREATS (NCT03739736)
- Testing
- Combination of TB/HIV prevention activities (arm A), Combination of TB/HIV prevention activities (arm B), Standard of care (arm C)
- Where
- 2 sites in South Africa, Zambia
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Latent Tuberculosis, Active Tuberculosis
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
Tuberculosis (TB) control remains a public health challenge. Many people in the UK do not have a general practitioner (GP) registration and their only interaction with the NHS is via Accident and Emergency (A\&E) Departments of…
- Trial name
- ACE (NCT02512484)
- Testing
- venepuncture, sputum collection, xray
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Public Health England
Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis
Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial
Tuberculosis increases energy demands and protein breakdown, leading to muscle wasting. Malnutrition and minimal weight gain less than 5% in first two months predict treatment failure.
- Conditions
- Tuberculosis Multi Drug Resistant Active, Rifampin-Resistant Pulmonary Tuberculosis, Pre-xdr tb
- Trial name
- NCT07058233
- Testing
- Oral nutritional supplementation
- Where
- Indonesia
- Volunteers
- 70 people
- Sponsor
- RSUP Persahabatan
Tuberculosis, Tuberculosis, Pulmonary
Point-of-care Triage Test for Active Tuberculosis
Background: Tuberculosis (TB) is a bacterial lung infection leaving 3.6 million people undiagnosed each year. Thirty percent of infected people do not receive treatment due to failure to receive diagnostic testing or being lost…
- Trial name
- TriageTB (NCT04232618)
- Testing
- Multi-biomarker point-of-care test
- Where
- South Africa
- Volunteers
- 900 people
- Sponsor
- University of Stellenbosch
Tuberculosis, Latent Tuberculosis
A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)
This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.
- Trial name
- TB-YOUTH (NCT06022146)
- Testing
- isoniazid and rifapentine, Rifampin and Isoniazid
- Where
- 66 sites in China
- Volunteers
- 3,520 people
- Sponsor
- Huashan Hospital
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG
Tuberculosis (TB)
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum…
- Trial name
- RADIO-TB (NCT07163143)
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- 4 sites in Pakistan, South Africa and 1 more
- Volunteers
- 784 people
- Sponsor
- University College, London
Tuberculosis
A Step Forward for Unraveling the Immune Mechanisms and Tools for Tuberculosis Spectrum Management
Tuberculosis (TB) is a significant infectious disease worldwide, with millions of people infected and major impact on mortality and public health.
- Trial name
- TB-SPECTRUM (NCT07735754)
- Volunteers
- 940 people, healthy volunteers welcome
- Sponsor
- Irene Latorre Rueda
Tuberculosis (TB), Tuberculosis in Children
Shorter Treatment Regimen Implementation Evaluation Study
"Evaluation of the implementation of the shorter treatment regimen for children and adolescents with non-severe TB in Zambia" is a parallel and convergent mixed methods evaluation study of implementation and clinical outcomes of…
- Conditions
- Tuberculosis (TB), Tuberculosis in Children, Tuberculosis Treatment Effectiveness, Tuberculosis Active
- Trial name
- EvSTR (NCT07747792)
- Where
- Zambia
- Volunteers
- 175 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
Tuberculosis
Precision Rifampin Trial for Personalized Dosing
Individual pharmacokinetic variability is an important driver of tuberculosis (TB) treatment failure particularly among undernourished populations, and that suboptimal serum drug concentrations are associated with delayed…
- Trial name
- P-RIF (NCT06318416)
- Testing
- urine spectrophotometry for rifampin absorbance
- Where
- Tanzania
- Volunteers
- 200 people
- Sponsor
- University of Virginia
BCG Vaccination Reaction, Tuberculosis
A Study of GC3107(BCG Vaccine) in Healthy Infants
The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants
- Trial name
- NCT03947138
- Testing
- GC3107, Intradermal BCG SSI inj.
- Where
- 2 sites in South Korea
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Tuberculosis, HIV Infections
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety…
- Trial name
- NCT01404312
- Testing
- Rifapentine (RPT), Isoniazid (INH), Pyridoxine (Vitamin B6)
- Where
- 45 sites in United States, Botswana and 8 more
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)